These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon. Furlanetto J; Marmé F; Loibl S Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628 [TBL] [Abstract][Full Text] [Related]
3. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. Schreiber AR; Andress M; Diamond JR Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524 [No Abstract] [Full Text] [Related]
4. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R; Hurvitz SA; Kalinsky K; Bardia A; Henry S; Mayer I; Zhu Y; Phan S; Cortés J Breast Cancer Res Treat; 2022 Sep; 195(2):127-139. PubMed ID: 35545724 [TBL] [Abstract][Full Text] [Related]
6. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Loriot Y; Petrylak DP; Rezazadeh Kalebasty A; Fléchon A; Jain RK; Gupta S; Bupathi M; Beuzeboc P; Palmbos P; Balar AV; Kyriakopoulos CE; Pouessel D; Sternberg CN; Tonelli J; Sierecki M; Zhou H; Grivas P; Barthélémy P; Tagawa ST Ann Oncol; 2024 Apr; 35(4):392-401. PubMed ID: 38244927 [TBL] [Abstract][Full Text] [Related]
7. Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer. Kang C Target Oncol; 2024 Mar; 19(2):289-296. PubMed ID: 38446351 [TBL] [Abstract][Full Text] [Related]
8. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. Fenn KM; Kalinsky K Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574 [TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. Shastry M; Jacob S; Rugo HS; Hamilton E Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269 [TBL] [Abstract][Full Text] [Related]
10. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Perrone E; Manara P; Lopez S; Bellone S; Bonazzoli E; Manzano A; Zammataro L; Bianchi A; Zeybek B; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Huang GS; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD Mol Oncol; 2020 Mar; 14(3):645-656. PubMed ID: 31891442 [TBL] [Abstract][Full Text] [Related]
11. Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. Mathew Thomas V; Tripathi N; Agarwal N; Swami U Expert Rev Anticancer Ther; 2022 Apr; 22(4):335-341. PubMed ID: 35249433 [TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. Goldenberg DM; Sharkey RM MAbs; 2019; 11(6):987-995. PubMed ID: 31208270 [TBL] [Abstract][Full Text] [Related]